CYTK
Cytokinetics Inc.
stockNASDAQ
At CloseOct 21, 2026 3:59:55 PM EDT
62.88USD-1.673%(-1.07)1,080,526
Loading…
Loading…
8.74B
Healthcare
Biotechnology
CEO
Robert Blum
HQ
South San Francisco, CA, USA
137
Previous Close
$63.95
Beta
0.81
52-Week High
$88.31 2026-06-30
52-Week Low
$54.30 2025-10-23
SMA 50
$69.71
SMA 200
$70.14
Avg. Vol 10D
1.72M
Avg. Vol 30D
2.09M
Avg. Vol 90D
2.08M
Relative Vol
0.37
139.02M
134.15M
96.49%
19,333,243
16.21%
8.37
57%/43%
72.53%
61.62%
0.4100%
1,400,000
2,845
65,223
98,000
Nov 4, 2026 (13d)
Jun 25, 2013 · 1-for-5.9999 (reverse)
67.7M
-894.0M
-580.7M
-1,046.12
Oct 21, 2026
Cytokinetics to Announce Third Quarter Results on November 4, 2026 · 
GlobeNewswire Inc.
Cytokinetics EVP Fady Malik sells over $224,000 in stock · 
Investing.com
Oct 19, 2026
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · GlobeNewswire Inc.
Oct 15, 2026
CYTK Profile
cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. as a leader in muscle biology and the mechanics of muscle performance, we're developing small molecule drug candidates specifically engineered to increase muscle function and contractility.
CYTK Performance
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 63.43 | 2026-10-14 | -0.87% | 3.019 |
| 1M | 67.56 | 2026-09-21 | -6.93% | -0.484 |
| 3M | 81.11 | 2026-07-21 | -22.48% | 0.125 |
| 6M | 65.80 | 2026-04-21 | -4.44% | 0.654 |
| 1Y | 57.78 | 2025-10-21 | +8.83% | 0.811 |
| 2Y | 53.81 | 2024-10-21 | +16.86% | — |
| 5Y | 36.21 | 2021-10-21 | +73.65% | 0.506 |
CYTK Stock Summary
Cytokinetics Inc. (NASDAQ:CYTK) stock price today is $62.88, and today's volume is 765,303. CYTK is down 1.673% today. The 30 day average volume is 2.09M. CYTK market cap is $8.74B with 139.02M shares outstanding.